Clinical trials: CIN 2
Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ
A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)
This study is designed to evaluate the immunogenicity, safety, and tolerability of Gardasil® (quadrivalent human papillomavirus [qHPV] vaccine, V501) in Chinese girls aged 9-19 years and young women aged 20-26 years.
- Trial name
- NCT03493542
- Testing
- V501
- Where
- China
- Volunteers
- 766 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Immunodeficiency Virus, HPV Infection
Thermocoagulation for Treatment of Precancerous Cervical Lesions
The purpose of this study is to evaluate the safety, acceptability, and efficacy of Thermocoagulation for treatment of precancerous lesions among HIV-positive women in a screen-and-treat program in Western Kenya.
- Conditions
- Human Immunodeficiency Virus, HPV Infection, CIN 2/3
- Trial name
- NCT04191967
- Testing
- Thermocoagulation
- Where
- Kenya
- Volunteers
- 379 people
- Sponsor
- University of California, San Francisco
HPV16 Positive, Cervical Intraepithelial Neoplasia (CIN 2/3)
Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)
This study will test the efficacy and safety of different routes of administration of a DNA vaccine in patients with HPV16+ CIN2/3. Subjects will be enrolled in one of six treatment groups.
- Trial name
- NCT00988559
- Testing
- DNA vaccination, Gene gun vaccine, intramuscular vaccination
- Where
- 3 sites in United States
- Volunteers
- 132 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Contrast Induced Nephropathy (CIN)
AVERT™ Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN
The Osprey Medical AVERT System is indicated to reduce contrast media (CM) exposure to the kidneys during percutaneous coronary procedures thereby reducing the risk of contrast induced nephropathy (CIN).
- Trial name
- AVERT™ (NCT01976299)
- Testing
- AVERT
- Where
- 39 sites in United States, Australia and 1 more
- Volunteers
- 578 people
- Sponsor
- Osprey Medical, Inc